Skip to main content

Table 4 Summary of ongoing clinical trials of immune therapies in patients with hepatocellulars carcinoma (HCC)

From: Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Type of immunotherapy Molecules NCT number Phase Population Estimated enrollment Recruitment status
Anti-PD-1 Pembrolizumab NCT03062358 III Advanced HCC, pre-treated 450 Recruiting
  Nivolumab NCT02576509 III Advanced HCC, naive 1720 Active, not recruiting
   NCT03383458 III Resected HCC 530 Recruiting
Combinations       
Anti-PD-1 + Anti CTLA-4 Durvalumab + tremelimumab NCT03298451 III Advanced HCC, naive 1310 Recruiting
  Nivolumab + ipilumumab NCT03510871 II Eligible for curative surgery 40 Not yet recruiting
   NCT03222076 II Resected HCC 45 Recruiting
Angiogenesis and ICI Nivolumab + bevacizumab NCT03382886 I Advanced HCC, pre-treated 12 Active, not recruiting
  Nivolumab + lenvatinib NCT03418922 I Advanced HCC, pre-treated and naive 30 Active, not recruiting
  Pembrolizumab + lenvatinib NCT03713593 III Advanced HCC, naive 750 Recruiting
Transarterial chemoembolization and ICI Nivolumab NCT03572582 II Intermediate stage HCC 49 Recruiting
  Durvalumab + tremelimumab NCT03638141 II Intermediate stage HCC 30 Recruiting
Y90-Radioembolization and Anti-PD-1 Nivolumab NCT03033446 II Advanced HCC 40 Recruiting
  1. CTLA-4 Cytotoxic T lymphocyte-associated protein 4; ICI immune checkpoint inhibitors; PD-1 programmed cell death-1; PD-L1 Programmed death-ligand 1